Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia ...

Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) ...

Venetoclax has made a significant impact in the treatment of chronic lymphocytic leukemia (CLL) due to its ability to induce deep and durable remissions with a finite duration of oral therapy. However ...

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.

"Patients with treatment-naive CLL have several treatment options, including continuous BTK inhibitor therapy, fixed-duration venetoclax-based regimens, and chemoimmunotherapy, for low-risk ...

Acalabrutinib and venetoclax, with or without obinutuzumab, improved PFS over chemoimmunotherapy in newly diagnosed CLL patients. The fixed-duration regimen offers potential cost savings and ...

Patients with CLL have several frontline treatment options, which include chemoimmunotherapy for low-risk disease as well as venetoclax plus the first-generation BTK inhibitor ibrutinib.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Developments in chronic lymphocytic leukemia (CLL) this ...